Leerink Partners Raises Axogen Price Target to $56 From $52
Leerink Partners maintained its Outperform rating and raised its price target from $52 to $56. The new target implies 13.7% upside from the Oct. 28 close of $49.25.
Leerink Partners maintained its Outperform rating and raised its price target from $52 to $56. The new target implies 13.7% upside from the Oct. 28 close of $49.25.